Overview

Dexmedetomidine in Off Pump Coronary Artery Bypass Grafting

Status:
Not yet recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
the study will assess the impact of intraoperative dexmedetomidine infusion on myocardial performance by investigating the left ventricular (LV) systolic and diastolic function and right ventricular (RV) fraction area change (which reflect RV systolic function) using two-dimensional trans-esophageal echocardiography (TEE) in patients undergoing elective first-time isolated off-pump coronary artery bypass (OPCAB) grafting. LV Systolic function will be measured by the TEE via the fractional area change, fraction shortening, and ejection fraction.
Phase:
N/A
Details
Lead Sponsor:
Suez Canal University
Treatments:
Dexmedetomidine